Antibody Drug Conjugates for Cancer Therapy

More documents

Recommendations

Info

Cumulative toxicity from long-lived intact ADC/TDCAcute toxicity <strong>for</strong>m unstable ADC/TDCDLTADCTDC03 6 9 12 15 18 21mg/kg <strong>Antibody</strong>-MMAE
In vivo efficacy of an antibody armed with a novel DNA Damaging Agent1500tumor volume (mm 3 )1000500vehiclecontrolsAnti-cd22-mk-DDA(1MPK)Anti-cd22-mk-DDA(5MPK)00 5 10 15 20 25 30Single IVDay
Page 1 and 2: Antibody Drug Conjugates for Cancer
Page 3: Target Screening- Large scale mRNA-
Page 6 and 7: Naked antibodies are likely to be i
Page 9 and 10: How many xenograft models should we
Page 11 and 12: RelativeTenB2 expression in human p
Page 13 and 14: Antibodies armed with auristatinsAN
Page 15: MRP4 (multi drug resistance protein
Page 18 and 19: Structure of the MUC16 antigen and
Page 20 and 21: Endothelin B receptor: A target for
Page 22 and 23: Melanocytes and EDNBR staining in n
Page 24 and 25: Increased cell killing in vitro wit
Page 26 and 27: ETBR Expression in Cell Lines versu
Page 28 and 29: Efficacy/SafetyFour ways for armed
Page 30 and 31: Antibody doses are normalized to dr
Page 32 and 33: In Vivo Efficacy is Retained With T
Page 36: • GNE ADC Team- Susan Spencer- Ke

Antibody Drug Conjugates for Cancer Therapy

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?